Tag: GlobeNewswire

FREEHOLD, NJ, Oct. 01, 2026 (GLOBE NEWSWIRE) — On October 1, 2026, the Board of Directors of UMH Properties, Inc. (NYSE: UMH; TASE: UMH) declared its quarterly cash dividend on the Company’s Common Stock of $0.225 per share payable December 15, 2026, to shareholders of record at the close of business on November 16, 2026. The Company’s annual dividend rate on its Common Stock is $0.90 per share.

Also, on October 1, 2026, the Board of Directors declared a quarterly dividend of $0.3984375 per share for the period from September 1, 2026, through November 30, 2026, on the Company’s 6.375% Series D Cumulative Redeemable Preferred Stock payable December 15, 2026, to shareholders of record at the close of business on November 16, 2026. Series D preferred share dividends are cumulative and payable quarterly at an annual rate of $1.59375 per share.

UMH Properties, Inc., which was organized in 1968, is a public equity REIT that owns and operates 145 manufactured home communities, containing approximately 27,100 developed homesites, of which 11,200 contain rental homes, and over 1,000 self-storage units. These communities are located in New Jersey, New York, Ohio, Pennsylvania, Tennessee, Indiana, Maryland, Michigan, Alabama, South Carolina, Florida and Georgia. Included in the 145 communities are two communities in Florida, containing 363 sites, and one community in Pennsylvania, containing 113 sites, that UMH has an ownership interest in and operates through its joint ventures with Nuveen Real Estate.

Contact:
Nelli Madden
732-577-9997

# # # # #

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) — ADARx Pharmaceuticals, Inc. (ADARx) (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today that, in connection with its upsized initial public offering of its common stock, the underwriters have fully exercised their option to purchase an additional 3,937,500 shares of ADARx’s common stock at a price to the public of $17.00 per share. The issuance of the additional shares closed on October 1, 2026, bringing the total number of shares sold in the initial public offering to 30,187,500 shares and the aggregate gross proceeds to ADARx from the offering, before deducting underwriting discounts and commissions and offering expenses payable by ADARx, to approximately $513.2 million.

J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank acted as lead book-running managers for the offering. LifeSci Capital acted as a book-running manager for the offering.

Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on September 24, 2026. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering was made only by means of a prospectus forming part of the registration statements relating to these securities. Copies of the final prospectus relating to the initial public offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at 1-866-718-1649, or by email at prospectus@morganstanley.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; or UBS Securities LLC, Attention: Equity Syndicate, 11 Madison Avenue, New York, NY 10010 or by email at ol-prospectus-request@ubs.com.

Including the purchase by AbbVie of 5,255,542 shares of ADARx’s common stock at a price of $17.00 per share in a concurrent private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the Securities Act), the aggregate gross proceeds to ADARx from the initial public offering and the concurrent private placement, before deducting underwriting discounts and commissions, placement agent fees and other offering and private placement expenses payable by ADARx, were approximately $602.5 million.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About ADARx Pharmaceuticals

ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company dedicated to transforming cutting-edge science into next-generation siRNA therapeutics. We have developed technology designed to control the expression of specific disease drivers with highly selective RNA targeted therapies with the goal of delivering life-changing treatments for patients with unmet medical needs. ADARx is focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, developing product candidates for the treatment of complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic (obesity) diseases. In addition to our wholly-owned programs, we have entered into a collaboration and license option agreement with AbbVie to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology.

CONTACT: Contacts

Investors: ir@adarx.com
Media: teri@redhousecomms.com

Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums

CERRITOS, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) — Starling Oncology™, Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today highlighted its leadership team’s active season of industry engagement, recapping recent conference participation and previewing upcoming appearances at major industry events.

These presentations reflect Starling Oncology’s role in advancing the science and practice of value-based community oncology. Across these forums, the Company’s physician leaders are sharing clinical insights drawn from its proprietary and innovative Starling Nexus™ utilization management platform and its community-based care model, including approaches to delivering novel therapies at scale, expanding clinical trial access, and integrating behavioral health into cancer care.

“Value-based oncology gives us the opportunity to align clinical innovation with better outcomes for patients. At Starling Oncology, our community-based model allows us to expand access to novel therapies and clinical trials while using evidence-based pathways to deliver high-quality, coordinated cancer care closer to where patients live,” said Yale D. Podnos, M.D., MPH, FACS, Chief Medical Officer and President of Practice of Starling Oncology.

“Community-based oncology practices remain the backbone of cancer care delivery in the United States. Yet practices operating within the traditional fee-for-service structure face increasing pressure from rising drug costs, IRA-related changes and biosimilar adoption. Starling Oncology’s coordinated care model and the recently launched Starling Nexus significantly reduce exposure to these pressures by realigning financial incentives for providers all while maintaining consistent levels of excellence in care,” said Jeffrey Langsam, D.O., Chief Clinical Officer of Starling Oncology.

Recent Presentations

• Deutsche Bank 2026 Healthcare Summit (New York, NY): Jeffrey Langsam, D.O., Chief Clinical Officer, participated in a panel titled “The Future of Oncology” on Thursday, September 17, 2026.
• The American Journal of Managed Care’s Patient-Centered Oncology Care^® (PCOC) Conference (Nashville, TN): Yale D. Podnos, M.D., MPH, FACS, Chief Medical Officer and President of Practice, participated in a panel titled “Cost Plus Capacity: Models for Delivering Novel Therapies at Scale” on Friday, September 25, 2026.

Upcoming Presentations

• Association for Value-Based Cancer Care (AVBCC) 2026 Summit (New York, NY): Dr. Podnos will join two panels on Thursday, October 8, 2026:
  • “New Economics, New Models for the Cancer Care Providers Ecosystem,” 4:00–4:50 p.m. ET
  • “Closing the Clinical Trial Gaps,” 5:00–5:50 p.m. ET
• America’s Physician Groups (APG) Fall Conference 2026 (National Harbor, MD): Dr. Podnos will present “Embedding Behavioral Health in Community Oncology: Measurement-Guided Collaborative Care at Scale” on Thursday, November 19, 2026.

Additional information about the Company’s events is available in the Investor Relations section of the Company’s website at https://investors.starlingoncology.com/.

About Starling Oncology, Inc.

Founded in 2007, Starling Oncology, Inc. (Nasdaq: STLN) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. Formerly known as The Oncology Institute, Starling Oncology offers cutting-edge, evidence-based cancer care to a population of approximately 2.1 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 400 employed and network clinicians and over 100 clinics and network locations of care across five states and growing, Starling Oncology is coordinating cancer care for the better. For more information visit www.starlingoncology.com. Please follow us on LinkedIn, X (formerly Twitter), or Bluesky.

Contacts

Media
ICR Healthcare
StarlingPR@icrhealthcare.com

Investors
ICR Healthcare
StarlingIR@icrhealthcare.com

WESTPORT, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) — Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, announced today that its Board of Directors (the “Board”) has declared a quarterly cash distribution for each of its three preferred share series.

The Board declared a quarterly cash distribution of $0.453125 per share on the Company’s 7.250% Series A Preferred Shares (the “Series A Preferred Shares”). The distribution on the Series A Preferred Shares covers the period from, and including, July 30, 2026, up to, but excluding, October 30, 2026. The distribution for such period is payable on October 30, 2026, to all holders of record of Series A Preferred Shares as of October 15, 2026.

The Board also declared a quarterly cash distribution of $0.4921875 per share on the Company’s 7.875% Series B Preferred Shares (the “Series B Preferred Shares”). The distribution on the Series B Preferred Shares covers the period from, and including, July 30, 2026, up to, but excluding, October 30, 2026. The distribution for such period is payable on October 30, 2026, to all holders of record of Series B Preferred Shares as of October 15, 2026.

The Board also declared a quarterly cash distribution of $0.4921875 per share on the Company’s 7.875% Series C Preferred Shares (the “Series C Preferred Shares”). The distribution on the Series C Preferred Shares covers the period from, and including, July 30, 2026, up to, but excluding, October 30, 2026. The distribution for such period is payable on October 30, 2026, to all holders of record of Series C Preferred Shares as of October 15, 2026.

CODI’s preferred cash distributions should generally constitute “qualified dividends” for U.S. federal income tax purposes to the extent they are paid from “earnings and profits” (as determined under U.S. federal income tax principles), provided that the requisite holding period is met. To the extent that the amount of cash distributions exceeds earnings and profits, such distribution will first be treated as a non-taxable return of capital to the extent of the holder’s adjusted tax basis in the shares and thereafter be treated as a capital gain from the sale or exchange of such shares.

About Compass Diversified (“CODI”)

CODI has consistently executed its strategy of owning and managing a diverse set of middle-market businesses. CODI leverages its permanent capital base and long-term, disciplined approach to maintain controlling ownership interests in each of its subsidiaries and maximize its ability to impact long-term cash flow generation and value creation. The Company provides both debt and equity capital for its subsidiaries, contributing to their financial and operating flexibility. CODI utilizes the cash flows generated by its subsidiaries to invest in the long-term growth of the Company and seeks to generate strong returns through its culture of transparency, alignment and accountability.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including without limitation, CODI’s expectations with respect to payment of its quarterly distributions and timing related to the same. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as “believe,” “expect,” “may,” “could,” “would,” “plan,” “intend,” “estimate,” “predict,” “future,” “potential,” “continue,” “should” or “anticipate” or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. These statements are based on beliefs and assumptions by CODI’s Board of Directors and management, and on information currently available to CODI’s Board of Directors and management. These statements involve risk and uncertainties that could cause actual results and outcomes to differ, perhaps materially, including but not limited to: changes in the economy, financial markets and political environment, including changes in inflation, interest rates and U.S. tariff and import/export regulations; risks associated with possible disruption in CODI’s operations or the economy generally due to terrorism, war, natural disasters, or social, civil or political unrest; future changes in laws or regulations (including the interpretation of these laws and regulations by regulatory authorities); environmental risks affecting the business or operations of our subsidiaries; disruption in the global supply chain, labor shortages and labor costs; our business prospects and the prospects of our subsidiaries; the impact of, and ability to successfully complete and integrate, acquisitions that we have made or may make; the ability to successfully complete when we’ve executed divestitures agreements; the dependence of our future success on the general economy and its impact on the industries in which we operate; the ability of our subsidiaries to achieve their objectives; the adequacy of our cash resources and working capital; the timing of cash flows, if any, from the operations of our subsidiaries; the cooperation of, and future concessions granted by, CODI’s lenders; control deficiencies identified or that may be identified in the future that will result in material weaknesses in CODI’s internal control over financial reporting; and litigation relating to the Lugano Holding, Inc. investigation, including CODI’s representations regarding its financial statements, and current and future litigation, enforcement actions or investigations relating to CODI’s internal controls, restatement reviews, the Lugano investigation or related matters. Please see CODI’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 27, 2026 and CODI’s other filings with the SEC for other risk factors that you should consider in connection with such forward-looking statements. Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date such statements have been made. Except as required by law, CODI does not undertake any public obligation to update any forward-looking statements to reflect events, circumstances, or new information after the date of this press release, or to reflect the occurrence of unanticipated events.

Compass Diversified Investor Relations
irinquiry@compassdiversified.com

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) — Antelope Enterprise Holdings Limited (NASDAQ Capital Market: AEHL) (“Antelope Enterprise”, “AEHL” or the “Company”), which provides livestreaming ecommerce services, business management and information systems consulting services in China, today announced that it has entered into an At-the-Market (“ATM”) Issuance Sales Agreement (the “Agreement”) dated October 1, 2026, under which the Company may, from time to time during the term of the Agreement, offer and sell the Company’s Class A ordinary shares (the “Shares”), for an aggregate offering price of up to $100 million, to or through D. Boral Capital LLC (the “Sales Agent”) as the Company’s sales agent or principal.

Sales of Shares, if any, will be made at or related to then-prevailing market prices and, as a result, prices may vary. The volume and timing of sales under the ATM Program (the “ATM Program”) will be determined at the Company’s discretion. The Company expects to use any proceeds from the ATM Program for general corporate purposes, including working capital, capital expenditures and other business purposes. The Company believes the ATM Program will further diversify its financing channels and strengthen its financial flexibility to support future strategic initiatives and capital activities.

Under the Agreement, the Sales Agent may sell the Shares as the Company’s sales agent or principal and by methods deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended. The maximum offering amount in the ATM Program will be $100 million or the maximum offering dollar amount permitted under the Company’s then current shelf registration capacity on the effective Registration Statement (defined below), whichever is lesser. In no event shall the aggregate number of Shares sold in the ATM Program exceed the number of the Company’s authorized but unissued Class A ordinary shares.

The Shares will be offered under the Company’s existing effective shelf registration statement on Form F-3 (No. 333-295047) (the “Registration Statement”) filed with the U.S. Securities and Exchange Commission (“SEC”). A prospectus supplement dated October 1, 2026 related to the offering has been filed with the SEC. Any offer, solicitation or sale will be made only by means of the prospectus supplement and the accompanying prospectus. Electronic copies of the prospectus supplement and the accompanying prospectus may be obtained from the SEC’s website at www.sec.gov or by contacting D. Boral Capital LLC, 590 Madison Ave 39th Floor, New York, NY 10022, or by email at info@dboralcapital.com, or by telephone at +1 (212) 970-5150. Current and potential investors should read the prospectus in the registration statement, and the prospectus supplement relating to the ATM Program and other documents the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more complete information about the Company and the ATM Program.

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor may there be any sale of the Company’s securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any state or jurisdiction.

About Antelope Enterprise Holdings Limited
Antelope Enterprise Holdings Limited (“Antelope Enterprise”, “AEHL” or the “Company”) holds a 51% ownership position in Hainan Kylin Cloud Services Technology Co. Ltd (“Kylin Cloud”), which operates a livestreaming e-commerce business in China. For more information, please visit our website at https://aehltd.com.

Safe Harbor Statement
Certain of the statements made in this press release are “forward-looking statements” within the meaning and protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause the actual results, performance, capital, ownership or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements in this press release include, without limitation, future Bitcoin market performance and developments in the Bitcoin industry, our ability to regain customers lost resulting in a decline in our revenues, the continued stable macroeconomic environment in the PRC, the consumer and technology sectors continuing to exhibit sound long-term fundamentals, our ability to continue as a going concern, our ability to raise capital to meet our capital needs, and our ability to continue to grow our business management, information system consulting, and online social commerce and live streaming business. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “will,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “point to,” “project,” “could,” “intend,” “target” and other similar words and expressions of the future.

All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in our transition report on Form 20-F for the transition period ended September 30, 2025 and otherwise in our SEC reports and filings. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC’s Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements otherwise are made.

Contact Information:

Antelope Enterprise Holdings Limited
Xiaoying Song, Chief Financial Officer
info@aehltd.com

WFS Investor Relations Inc.
Email: services@wfsir.com
+1 628 283 9214

NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on September 30, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to 4 new employees, stock options to purchase an aggregate of 85,900 shares of the Company’s common stock, with a per share exercise price of $10.44.

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying the award on the first anniversary of the employee’s start date, and the remaining 75% of the shares of common stock underlying the inducement stock options will vest in 36 equal monthly installments thereafter. All vesting related to inducement awards is subject to the employees’ continuing service at the Company through the applicable vesting date.

The above-described awards were each granted as inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by the Board on December 24, 2025.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (or aglatimagene) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA) and published in The Lancet Oncology. The FDA also granted Fast Track Designation, Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.

Linoserpaturev is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com

Investor Contact
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com

Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com

Non-binding memorandum contemplates a joint venture pairing Plume’s tokenisation infrastructure with AsiaStrategy’s and Sora Ventures’ distribution across Asia, positioning the Company for what it believes will be a structural shift in how financial assets are issued, held, and traded

Hong Kong, Oct. 01, 2026 (GLOBE NEWSWIRE) — AsiaStrategy (Nasdaq: SORA) today announced that it has entered into a non-binding memorandum of understanding with Plume, the Open Finance platform for institutional assets, to explore the formation of a joint venture focused on the structuring, issuance, and distribution of tokenised financial products to investors in Asia and other markets outside the United States.

The memorandum contemplates a division of responsibilities that reflects what each party brings. Plume would contribute its tokenisation infrastructure, technical know-how, and regulatory standing, which includes registrations and licences held in several jurisdictions. AsiaStrategy, together with the wider Sora Ventures network, would contribute origination, distribution, and capital markets access across the Asian markets in which the group is active, including Japan, Korea, Hong Kong, Thailand, and the United Arab Emirates.

The parties intend to work initially on products that pair established asset classes with compliant on-chain distribution, with scope to broaden the range over time as the market develops. Product scope, structuring, and sequencing remain under discussion, and no product has been launched or offered to investors.

The Company views tokenisation as one of the more consequential developments in financial infrastructure of the coming decade. Regulatory frameworks for digital assets have advanced materially across Asia and the Gulf, institutional appetite for on-chain settlement and distribution has moved from pilot to production, and the direction of travel across the major financial centres is now toward accommodation rather than restriction. AsiaStrategy believes the parties that combine licensed technical infrastructure with genuine distribution will be positioned to capture a disproportionate share of that transition, and intends to be among them.

For AsiaStrategy, the initiative is intended to extend the Company’s activities into a financialisation layer that sits alongside its Bitcoin treasury and its digital-asset pledging business. Where the pledging business generates revenue from deploying the Company’s balance sheet, a tokenisation platform is intended over time to generate revenue from structuring, distribution, and platform activity: a stream that would scale with the volume of assets brought on-chain rather than with the size of the Company’s own balance sheet. The Company regards that combination of a hard-asset treasury, a credit business, and a platform layer as a durable foundation for growth through market cycles.

“We think tokenisation ends up being the default way a great many financial assets are issued and held, and Asia is where that happens first,” said Jason Fang, Chairman and Co-Chief Executive Officer of AsiaStrategy. “Plume has taken the harder route of building inside the licensed perimeter rather than around it, which is the only version of this that scales to institutional size. What we and Sora Ventures bring is the other half of the equation: relationships with the issuers, institutions, and capital pools in this region that decide whether a product actually gets distributed. Put those two halves together and you have something with real reach.”

The memorandum is non-binding, and the joint venture remains subject to definitive documentation, internal approvals, and applicable regulatory requirements. The parties intend that any activity conducted under the proposed venture will be undertaken within licensed frameworks in each relevant jurisdiction, and that distribution will not be directed at United States persons unless and until the applicable requirements are satisfied.

“Our approach to new business lines has not changed,” Mr Fang added. “We ask whether it adds durable earnings power, whether we can execute it compliantly, and whether it compounds value for shareholders. Tokenisation clears the first test comfortably on any reasonable view of where this market is heading, and this memorandum is how we address the second and third. We would rather be early and properly built than late and well documented.”

About AsiaStrategy

AsiaStrategy (Nasdaq: SORA) is a Cayman-incorporated, Hong Kong-headquartered luxury watches trading company diversified into Bitcoin and digital asset treasury. Its activities span Bitcoin treasury management, digital-asset-collateralised lending, compute infrastructure, and related financing and tokenisation initiatives across Asia and beyond, with a focus on Japan, Korea, Hong Kong, and Thailand.

About Plume

Plume is the Institutional Open Finance platform. It brings institutional assets out of closed financial systems into open, programmable, globally accessible markets. Plume Vaults, Plume’s flagship asset management protocol, opens institutional assets from Apollo, WisdomTree, Hamilton Lane, and other leading firms to global investors through compliant, non-custodial vaults. Backed by Apollo Global Management, Galaxy Digital, and Brevan Howard. It holds a SEC transfer-agent registration via Kimber Transfer Agency LLC and a licence from the Bermuda Monetary Authority.

Investor & Media Contact

AsiaStrategy Investor Relations
contact@asiastrategy.io | asiastrategy.io

Forward-Looking Statements

This release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the proposed joint venture with Plume Network, the products and services that may be developed or distributed under it, the Company’s tokenisation strategy, the anticipated revenue characteristics of any resulting business, and management’s expectations as to the growth, regulatory development, and institutional adoption of tokenised financial assets generally. Such statements reflect management’s current expectations and assumptions and are subject to risks and uncertainties, including the failure to agree definitive documentation, the possibility that tokenisation markets develop more slowly or differently than anticipated, regulatory developments in the jurisdictions in which the parties operate, technology and counterparty performance risk, digital asset price volatility, and the availability of financing. The memorandum of understanding described in this release is non-binding, and no assurance can be given that any venture, transaction, or product described will be entered into, launched, or completed on the terms described, or at all. Actual results may differ materially from those expressed or implied. Investors should not place undue reliance on forward-looking statements and should refer to the risk factors set out in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update these statements except as required by law.

MENLO PARK, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) — Today, Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) announced that it will release its third quarter 2026 financial results on Tuesday, October 27, 2026, after market close. Robinhood will host a video call with Chairman & Chief Executive Officer Vlad Tenev and Chief Financial Officer Shiv Verma to discuss its results at 2:00 PM PT / 5:00 PM ET on the same day. The video call and supporting materials will be available at investors.robinhood.com. The event will also be live streamed to YouTube and X.com via Robinhood’s official channels, @RobinhoodApp, and within the Robinhood mobile app. Following the call, a replay and transcript will be available at investors.robinhood.com.

Ahead of the call, Robinhood shareholders can visit https://app.saytechnologies.com/robinhood-markets-2026-q3 to submit and upvote questions for management using the Q&A platform developed by Say by Robinhood. The Q&A platform will be open for question submission starting Tuesday, October 20, 2026, at 2:00 PM PT / 5:00 PM ET. Shareholders will be able to submit and upvote questions until Monday, October 26, 2026, at 2:00 PM PT / 5:00 PM ET. Management will address a selection of the most upvoted questions relating to Robinhood’s business and financial results on the earnings call. Shareholders can email hello@saytechnologies.com for any support inquiries.

About Robinhood

Robinhood Markets, Inc. (NASDAQ: HOOD) is a global leader in financial services offering retail brokerage, crypto, advisory, digital banking services, and private markets access to a new generation of investors. Additional information about Robinhood can be found at robinhood.com.

Robinhood uses the “Overview” tab of its Investor Relations website (accessible at investors.robinhood.com/overview) and its Newsroom (accessible at newsroom.aboutrobinhood.com), as means of disclosing information to the public in a broad, non-exclusionary manner for purposes of the U.S. Securities and Exchange Commission (SEC) Regulation Fair Disclosure (Reg. FD). Investors should routinely monitor those web pages, in addition to Robinhood’s press releases, SEC filings, and public conference calls and webcasts, as information posted on them could be deemed to be material information.

“Robinhood” and the Robinhood feather logo are registered trademarks of Robinhood Markets, Inc. All other names are trademarks and/or registered trademarks of their respective owners.

Contacts

Investor Relations: ir@robinhood.com

Press: press@robinhood.com

CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,150 restricted stock units (“RSUs”) to one newly hired employee.

The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.

This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com and follow us on LinkedIn at Solid Biosciences and X at @Solid_Bio.

Solid Biosciences Investor Contact:
Nicole Anderson
Senior Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Amir Khan
Corporate Affairs Practice
Syneos Health
amir.khan@Syneoshealth.com
(347) 249-0230

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) has scheduled its third quarter 2026 financial results announcement.

	Who:		Nasdaq’s CEO, CFO, and additional members of its senior management team
	What:		Review Nasdaq’s third quarter 2026 financial results
	When:		Thursday, October 22, 2026
			Results Call: 8:00 AM Eastern

Senior management will be available for questions from the investment community following prepared remarks.

All participants can access the conference via webcast through the Nasdaq Investor Relations website at http://ir.nasdaq.com/.

Note: The press release and results presentation for the third quarter 2026 results will be posted on the Nasdaq Investor Relations website at http://ir.nasdaq.com/ on Thursday, October 22, 2026 at approximately 7:00 AM Eastern.

About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a leading technology platform that powers the world’s economies. We architect the infrastructure of the world’s most modern markets, power the innovation economy, and build trust in the financial system. We empower economic opportunity by designing and deploying advanced technology, data, and intelligence solutions that enable our clients to capture opportunities, navigate risk, and strengthen resilience. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

Media Relations Contact:
David Lurie
+1.914.538.0533
David.Lurie@Nasdaq.com

Investor Relations Contact:
Ato Garrett
+1.212.401.8737
Ato.Garrett@Nasdaq.com

-NDAQF-